2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - La Nouvelle C
Chimeric Antigen Receptor T cell therapies have transformed the outcomes of patients with relapsed and refractory multiple myeloma and its role continues to expand at a rapid pace. This session brings together cutting edge data spanning novel approaches to improve the safety and efficacy of CAR-T products in the clinic. Presenters will explore how new strategies are changing the efficacy and safety balance to reshape treatment paradigms as the field pushes towards deeper and more durable responses. Attendees will get insights into latest clinical data in this important session.
Treatment Considerations, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult
PAPER

271 Post-CAR-T consolidation with fixed-duration BCMA-directed bispecific antibody therapy: Results from the phase II trial of elranatamab post-idecabtagene vicleucel (EPIC) in patients with relapsed or refractory multiple myeloma

Benjamin Robert Puliafito, MD, Matthew Lei, PharmD2, Andrew J. Yee, MD3, Omar Nadeem, MD4, Diana D Cirstea, MD5, Andrew Branagan, MD, PhD6, Emerentia Agyemang, CNP7, Kelley Grealish8, Kacthary Sanclemente, RN9, Lisette Packer, RN10, Mollie Furtado, RN11, Kareem Mosaheb12, Alexis Barselau13, Keira Thompson14, Alexandra Wright, BS15, Taylor Nicholson16, Emily Simpson, RN17, Keemia Mohammadi18, Eric Hua, BS19, Rajib Shome, PhD20, Advait Joshi, MBBS21, Nora Horick22, Matthew Frigault, MD23, Jacalyn Rosenblatt, MD24, Nikhil Munshi, MD25, Jacob Laubach, MD26, Noopur Raje, MD27
1 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
2 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
3 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
6 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
7 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
8 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
9 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
10 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
11 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
12 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
13 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
14 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
15 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
16 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
17 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
18 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
19 Beth Israel Deaconess Medical Cancer Center, Boston, Massachusetts, United States
20 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
21 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
22 Massachusetts General Hospital, Boston, Massachusetts, United States
23 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
24 Beth Israel Deaconess Medical Cancer Center, Boston, Massachusetts, United States
25 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
26 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
27 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States

Bispecific antibodies may improve outcomes as post-CAR-T consolidation by re-invigorating anti-myeloma T-cell responses. We report results of the EPIC trial, an ongoing investigator-initiated phase 2 study of elranatamab (Elra) as a fixed-duration consolidation after idecabtagene vicleucel (ide-cel) CAR-T cell therapy (NCT06138275).

Eligible patients (pts) had received ide-cel as standard of care for relapsed or refractory multiple myeloma after ≥2 prior lines of therapy (LOTs) without progressive disease after ide-cel. Pts received Elra consolidation for 6 cycles starting between Day +100 and +160 after ide-cel. Elra schedule included step-up dosing followed by weekly dosing for cycles 1 and 2 and every other week dosing for cycles 3-6. The primary endpoint was progression-free survival (PFS). Secondary endpoints include adverse events (AEs), IMWG response, and MRD-negativity to 10−6 sensitivity using a next-generation sequencing or flow cytometry-based assay. Exploratory correlative studies include assessing changes in T-cell phenotype and ide-cel persistence. Data cutoff was April 15, 2026.

25 pts started Elra consolidation at a median of 3.8 months from ide-cel (range, 3.0-5.2 mo); 23 pts have completed at least one cycle and were evaluable for response. The median age was 67 (range, 48-82). Seven pts (28%) had high-risk cytogenetics [defined by t(4;14), t(14;16), or del(17p)] and 4 pts (16%) had a history of extramedullary disease. The median number of prior LOTs was 3 (range, 2-6). 13 pts (52%) received Elra step-up dosing as an outpatient.

With a median follow-up of 9.8 months from Elra initiation (range, 1.8 - 22.6 mo), the median PFS has not yet been reached (95% CI, not evaluable). The 12-month PFS rate from ide-cel infusion was 94.4% (95% CI, 66.6–99.2%). As of the data cutoff, 3 pts (13%) had an ongoing response beyond 24 months from ide-cel infusion. Only one pt (4%) has had PD, at 7.2 months from Elra initiation. This patient had a solitary cutaneous plasmacytoma treated with excision and radiation, and has remained off systemic therapy up to 23 months after Elra initiation.

Of the pts who had completed at least one cycle of Elra, 61% (n=14/23) started Elra with a best response of ≤VGPR post-ide-cel (SD: n=2, PR: n=9, VGPR: n=3) and 39% (n=9/23) started with a best response of CR/sCR. 100% of the pts with ≤VGPR post-ide-cel (n=14/14) had deepening of their IMWG response. The best overall response after Elra among the 23 evaluable pts was CR/sCR in 83% (n=19/23) and VGPR in 17% (n=4/23). 11 pts had evaluable MRD samples at screening and after completing or discontinuing Elra consolidation. Five pts (45%) had conversion from MRD-positivity to MRD-negativity at 10−6 sensitivity and 5 pts (45%) remained MRD-negative from screening through Elra completion. One pt (9%) lost MRD-negativity after discontinuing Elra.

CRS occurred in 11 pts (n=11/25; 44%), predominately grade (Gr) 1 with 2 pts (8%) having Gr 2 CRS. No ICANS occurred. Gr 3 or 4 hematologic AEs occurred in 11 pts (44%; neutropenia: n=10, 40%, anemia: n=4, 16%, thrombocytopenia: n=3, 12%). Gr 3 or 4 non-hematologic AEs occurred in 9 pts (36%). Infections occurred in 14 pts (56%) with Gr 3 or 4 infections occurring in 5 pts (20%). CMV viremia occurred in 6 pts (24%), with only one pt requiring CMV-directed treatment while the other 5 pts had resolution of CMV viremia without intervention. All patients received IVIG.

Fixed-duration consolidation with elranatamab after ide-cel led to deepening of disease responses and MRD-conversion with the majority of patients progression-free at 12 months after ide-cel, demonstrating ongoing, durable responses.

Benjamin Robert Puliafito, MD: Sanofi - Consultancy (Includes expert testimony); Legend Biotech - Consultancy (Includes expert testimony)